Pipeline
Biographies
Investors
News
Careers
Contact
Vantia Ltd
Southampton
Science Park
1 Venture Road
Chilworth
Southampton
SO16 7NP
United Kingdom
t +44 23 8076 3400
f +44 23 8076 6755
info@vantia.com
Vantia Therapeutics is a leading research based healthcare company dedicated to improving clinical treatments through development & commercialisation of innovative medicines.
Vantia was formed in late 2007, and acquired a series of assets & people from Ferring Research Ltd in March 2008.
Vantia is a new company with 21 years experience in small molecule discovery & early development. The new Management Team led by Jim Phillips (CEO) is adding to that a Clinical Development & Commercialisation capability.
Vantia is based in Southampton University's Science Park in the United Kingdom, where our team of 16 scientists have fully equipped facilities for Medicinal Chemistry, DMPK, and Lead Discovery.
Vantia is planning to develop its lead products over the next two years to the point where larger pharmaceutical companies will partner the programs from us.
VA106483 Phase IIa trial in nocturia
29 June 2009
Vantia Therapeutics' lead candidate VA106483 demonstrates positive anti-diuretic effect
in Phase IIa trial in nocturia.
» more
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
21 April 2009
Vantia Therapeutics, a company developing novel small molecule drugs targeting large underserved medical markets,
today announces the appointment of Rachel Morten as Head of Regulatory Affairs.
» more
Vantia TherapeuticsÂ’ Pipeline Continues to Mature
24 March 2009
VA106483 completes Phase IIa trial and VA111913 completes Phase I dosing
» more
An Introduction to Vantia Therapeutics
11 february 2008
Vantia Therapeutics presents an updated, non-confidential Corporate Overview of R&D
» more
BioCentury interview with Vantia's CEO, Jim Phillips
26 November 2008
Jim Phillips, CEO of Vantia Therapeutics, talks to BioCentury about Vantia's rapid progress.
» more
Vantia Therapeutics progresses clinical development of lead drug candidates
3 November 2008
Vantia Therapeutics progresses clinical development of lead drug candidates.
» more
New UK R&D company
19 March 2008
Vantia Therapeutics, launched with backing from
MVM Life Science Partners, SV Life Sciences and Novo A/S
» more